Benefits of Docetaxel for Metastatic Castration-Resistant Prostate Cancer Sudanese Patients and the Effective Number of Cycle and Dose (2013–2017)
Mawahib Ahmed Elawad Abu Elgasim, Yousra Abdelmoniem Suleiman, Ehssan M. Elnazir Ahmed ELmubark, Alaa Albukhari Alrayah Abdalmahmoud, Sujood Abdelmoneim Mohmmed Babkeir, Rogaia Omer, Rayayan Yasin, Khalida Esmaiel Adam Abaker, Roa Osman Ahmed Babker, Anfal Abdalrhman Alryah & Thowibaah Abdalrhman Alzain · International Research Journal of Oncology · 2019
Background: Prostate cancer remains the most common cancer in men worldwide and in Sudanese people. The initial treatment of choice for prostate cancer is androgen deprivation. If resistant to treatment, this leads to a state termed metastatic castration-resistant prostate cancer...